secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0000950170-25-108835
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health Q2 revenue down 39% to $86k; net loss widens to $1.9M; plans to exit ClearUP, focus on biopharma
--------------------------------------------------------------------------------

- Revenue $86k (-39% YoY); net loss $1.9M vs $1.3M in Q2 2024; cash $1.2M at June 30.
- Raised $0.9M post-quarter; $7M committed via preferred equity; no debt on balance sheet.
- Plans to exit ClearUP consumer healthtech by year-end; shifts resources to TLR5 agonist Entolimod.
- Extended Entolimod license to include neutropenia; completed study visits for ncVNS device.
- Named Lisa Wolf as permanent CFO; expanded biopharma team with regulatory and clinical staff.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025108835/0000950170-25-108835-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025108835/tivc-20250814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-108835

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer